{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:58:56Z","timestamp":1779235136517,"version":"3.51.4"},"reference-count":48,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Targets of curative donor-derived graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT) remain poorly defined, partly because immunity against minor histocompatibility Ags (mHAgs) complicates the elucidation of multiple myeloma (MM)\u2013specific targets. We hypothesized that syngeneic HSCT would facilitate the identification of GVM-associated Ags because donor immune responses in this setting should exclusively target unique tumor Ags in the absence of donor-host genetic disparities. Therefore, in the present study, we investigated the development of tumor immunity in an HLA-A0201+ MM patient who achieved durable remission after myeloablative syngeneic HSCT. Using high-density protein microarrays to screen post-HSCT plasma, we identified 6 Ags that elicited high-titer (1:5000-1:10 000) Abs that correlated with clinical tumor regression. Two Ags (DAPK2 and PIM1) had enriched expression in primary MM tissues. Both elicited Ab responses in other MM patients after chemotherapy or HSCT (11 and 6 of 32 patients for DAPK2 and PIM1, respectively). The index patient also developed specific CD8+ T-cell responses to HLA-A2\u2013restricted peptides derived from DAPK2 and PIM1. Peptide-specific T cells recognized HLA-A2+ MM-derived cell lines and primary MM tumor cells. Coordinated T- and B-cell immunity develops against MM-associated Ags after syngeneic HSCT. DAPK1 and PIM1 are promising target Ags for MM-directed immunotherapy.<\/jats:p>","DOI":"10.1182\/blood-2011-11-388926","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T01:01:47Z","timestamp":1327107707000},"page":"3142-3150","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation"],"prefix":"10.1182","volume":"119","author":[{"given":"Melinda A.","family":"Biernacki","sequence":"first","affiliation":[{"name":"University of Connecticut School of Medicine, Farmington, CT;"},{"name":"Cancer Vaccine Center and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-tzu","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anselmo","family":"Alonso","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wandi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rao","family":"Prabhala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"},{"name":"Veterans Administration Boston Healthcare System, West Roxbury, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Brusic","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Vaccine Center and"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2019111807435526200_B1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"10","key":"2019111807435526200_B2","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"issue":"10","key":"2019111807435526200_B3","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2019111807435526200_B4","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2019111807435526200_B5","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111807435526200_B6","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1084\/jem.20011925","article-title":"Fc gamma receptors and cross-presentation in dendritic cells.","volume":"195","author":"Amigorena","year":"2002","journal-title":"J Exp Med"},{"issue":"3","key":"2019111807435526200_B7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle.","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"issue":"9004","key":"2019111807435526200_B8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","article-title":"Graft-versus-myeloma effect in two cases.","volume":"347","author":"Verdonck","year":"1996","journal-title":"Lancet"},{"issue":"11","key":"2019111807435526200_B9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111807435526200_B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00062752-200211000-00005","article-title":"Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.","volume":"9","author":"Falkenburg","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"2019111807435526200_B11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF03165108","article-title":"Minor histocompatibility antigens\u2013targets of graft versus leukemia responses.","volume":"76","author":"Riddell","year":"2002","journal-title":"Int J Hematol"},{"issue":"4","key":"2019111807435526200_B12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood-2006-06-030858","article-title":"Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation.","volume":"109","author":"Mullally","year":"2007","journal-title":"Blood"},{"key":"2019111807435526200_B13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0065-2776(06)90004-2","article-title":"Induction of tumor immunity following allogeneic stem cell transplantation.","volume":"90","author":"Wu","year":"2006","journal-title":"Adv Immunol"},{"issue":"14","key":"2019111807435526200_B14","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1158\/1078-0432.CCR-09-0199","article-title":"Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.","volume":"15","author":"Nishida","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111807435526200_B15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood-2003-07-2559","article-title":"Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.","volume":"103","author":"Bellucci","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111807435526200_B16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/0008-5472.CAN-09-2303","article-title":"Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.","volume":"70","author":"Biernacki","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"2019111807435526200_B17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/0008-5472.CAN-09-3143","article-title":"Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.","volume":"70","author":"Marina","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2019111807435526200_B18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI10196","article-title":"Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.","volume":"106","author":"Wu","year":"2000","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111807435526200_B19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.","volume":"204","author":"Spisek","year":"2007","journal-title":"J Exp Med"},{"issue":"5","key":"2019111807435526200_B20","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1021\/pr700892h","article-title":"A concentration-dependent analysis method for high density protein microarrays.","volume":"7","author":"Marina","year":"2008","journal-title":"J Proteome Res"},{"key":"2019111807435526200_B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-61779-043-0_16","article-title":"A coprecipitation-based validation methodology for interactions identified using protein microarrays.","volume":"723","author":"Marina","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2019111807435526200_B22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","article-title":"Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.","volume":"6","author":"Ladetto","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111807435526200_B23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0161-5890(95)00065-8","article-title":"Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling.","volume":"33","author":"Lim","year":"1996","journal-title":"Mol Immunol"},{"issue":"5","key":"2019111807435526200_B24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CJI.0b013e31819f1cb6","article-title":"Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells.","volume":"32","author":"Tur","year":"2009","journal-title":"J Immunother"},{"issue":"10","key":"2019111807435526200_B25","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.bbmt.2008.07.007","article-title":"Comparison of twin and autologous transplants for multiple myeloma.","volume":"14","author":"Bashey","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111807435526200_B26","first-page":"527","article-title":"Syngeneic marrow transplantation in patients with multiple myeloma.","volume":"18","author":"Bensinger","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111807435526200_B27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.bmt.1701975","article-title":"Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation.","volume":"24","author":"Gahrton","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111807435526200_B28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00432-008-0499-7","article-title":"Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma.","volume":"135","author":"Kopp","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"2019111807435526200_B29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0301-472X(02)00794-4","article-title":"Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.","volume":"30","author":"Ladetto","year":"2002","journal-title":"Exp Hematol"},{"issue":"10","key":"2019111807435526200_B30","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111807435526200_B31","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ncb1618","article-title":"PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.","volume":"9","author":"Zippo","year":"2007","journal-title":"Nat Cell Biol"},{"issue":"15","key":"2019111807435526200_B32","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.ejca.2008.06.044","article-title":"Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.","volume":"44","author":"Shah","year":"2008","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019111807435526200_B33","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/emboj\/16.5.998","article-title":"DAP-kinase is a Ca2+\/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity.","volume":"16","author":"Cohen","year":"1997","journal-title":"EMBO J"},{"issue":"4","key":"2019111807435526200_B34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.onc.1201172","article-title":"DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene.","volume":"15","author":"Kissil","year":"1997","journal-title":"Oncogene"},{"issue":"6","key":"2019111807435526200_B35","first-page":"1724","article-title":"Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma.","volume":"7","author":"Ng","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2019111807435526200_B36","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111807435526200_B37","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-08-3332","article-title":"Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.","volume":"15","author":"Beatty","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111807435526200_B38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","article-title":"High-throughput oncogene mutation profiling in human cancer.","volume":"39","author":"Thomas","year":"2007","journal-title":"Nat Genet"},{"issue":"7339","key":"2019111807435526200_B39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma.","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111807435526200_B40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1172\/JCI44581","article-title":"Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.","volume":"121","author":"Lin","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111807435526200_B41","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/art.24715","article-title":"Apoptotic cell blebs: repositories of autoantigens and contributors to immune context.","volume":"60","author":"Suber","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2019111807435526200_B42","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/1078-0432.CCR-10-0415","article-title":"Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.","volume":"16","author":"Zhang","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111807435526200_B43","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","article-title":"Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.","volume":"109","author":"Atanackovic","year":"2007","journal-title":"Blood"},{"issue":"39","key":"2019111807435526200_B44","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.","volume":"103","author":"J\u00e4ger","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111807435526200_B45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20011097","article-title":"Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.","volume":"195","author":"Dhodapkar","year":"2002","journal-title":"J Exp Med"},{"issue":"23","key":"2019111807435526200_B46","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1158\/0008-5472.CAN-08-2233","article-title":"Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.","volume":"68","author":"Saenger","year":"2008","journal-title":"Cancer Res"},{"issue":"21","key":"2019111807435526200_B47","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8 T cells through cross-priming.","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111807435526200_B48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-1-61779-043-0_21","article-title":"Data processing and analysis for protein microarrays.","volume":"723","author":"DeLuca","year":"2011","journal-title":"Methods Mol Biol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/13\/3142\/1349735\/zh801312003142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/13\/3142\/1349735\/zh801312003142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:56:29Z","timestamp":1574063789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/13\/3142\/29651\/Novel-myelomaassociated-antigens-revealed-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,29]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,3,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-388926","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,29]]}}}